Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathw… Read more
Glaukos Corp - Asset Resilience Ratio
Glaukos Corp (GKOS) has an Asset Resilience Ratio of 17.56% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Glaukos Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Glaukos Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $175.47 Million | 17.56% |
| Total Liquid Assets | $175.47 Million | 17.56% |
Asset Resilience Insights
- Good Liquidity Position: Glaukos Corp maintains a healthy 17.56% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Glaukos Corp Industry Peers by Asset Resilience Ratio
Compare Glaukos Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for Glaukos Corp (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Glaukos Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.32% | $149.29 Million | $974.76 Million | -6.16pp |
| 2023-12-31 | 21.48% | $201.96 Million | $940.41 Million | -0.23pp |
| 2022-12-31 | 21.71% | $233.17 Million | $1.07 Billion | -6.05pp |
| 2021-12-31 | 27.76% | $313.34 Million | $1.13 Billion | -2.85pp |
| 2020-12-31 | 30.61% | $307.77 Million | $1.01 Billion | +16.98pp |
| 2019-12-31 | 13.63% | $111.55 Million | $818.40 Million | -39.84pp |
| 2018-12-31 | 53.47% | $110.67 Million | $206.97 Million | -3.52pp |
| 2017-12-31 | 56.99% | $94.51 Million | $165.84 Million | -9.45pp |
| 2016-12-31 | 66.43% | $89.27 Million | $134.37 Million | +6.82pp |
| 2015-12-31 | 59.62% | $69.55 Million | $116.66 Million | +59.39pp |
| 2014-12-31 | 0.23% | $60.00K | $26.02 Million | +0.04pp |
| 2013-12-31 | 0.19% | $60.00K | $30.88 Million | -- |